Search
BioMarin Pharmaceutical Inc
BMRNAdd to Watchlist
57.670USD
-1.330-2.25%
Close 06/29, 16:00（ET）Quotes delayed by 15 min
11.15BMarket Cap
41.34P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-2.25%
5 Days
+3.17%
1 Month
+0.66%
6 Months
-3.95%
Year to Date
-2.96%
1 Year
+4.53%
Key Figures
59.280Open
59.425High
1.80MVolume
41.34P/E TTM
10.13P/E Dynamic
--Dividend TTM
0.93%Turnover Ratio
59.000Prev. Close
56.850Low
79.19MTurnover
26.11P/E Static
1.79P/B
0.00%Div Yield TTM
3.42%ROA
66.27552wk High
0.69Volume Ratio
426.86MNet Profit
193.27MShares
1.3951EPS TTM
0.22Beta
4.48%ROE
49.25952wk Low
4.36%Amplitude
73.97%Gross Margin
11.15BMarket Cap
1.56Reward/Risk
1.91%Risk Rate
TradingKey Stock Score of BioMarin Pharmaceutical Inc
Currency: USD Updated: 2026-06-29Key Insights
BioMarin Pharmaceutical Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 18 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 89.14.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioMarin Pharmaceutical Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
BioMarin Pharmaceutical Inc Highlights
StrengthsRisks
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 33.15% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.22B.
Fairly Valued
The company’s latest PE is 41.34, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 192.89M shares, decreasing 7.00% quarter-over-quarter.
Held by Andreas Halvorsen
Star Investor Andreas Halvorsen holds 7.62M shares of this stock.
Analyst Rating
Based on
28
analysts
Buy
Current Rating
89.141
Target Price
+51.09%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioMarin Pharmaceutical Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
BioMarin Pharmaceutical Inc Info
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
Ticker SymbolBMRN
CompanyBioMarin Pharmaceutical Inc
CEOHardy (Alexander)
Websitehttps://www.biomarin.com/
Related Instruments
+1.74%
+1.48%
+0.30%
+0.56%
+1.38%
+1.38%
+0.62%
+0.56%
-1.21%
+0.39%
+1.69%
+1.79%
+0.59%
+1.12%
-2.09%
0.00%
-0.17%
+2.85%
-0.74%
+0.47%Popular Instruments
52290.500
+137.300 (+0.26%)
29859.500
+151.800 (+0.51%)
7453.300
+21.100 (+0.28%)
15579.000
+128.000 (+0.83%)
70129.000
-345.000 (-0.49%)
6312.200
+56.400 (+0.90%)
70.491
+0.175 (+0.25%)
281.740
-2.040 (-0.72%)
194.970
+2.440 (+1.27%)
4031.350
+15.760 (+0.39%)
FAQs
What is the current price of BioMarin Pharmaceutical Inc (BMRN)?
The current price of BioMarin Pharmaceutical Inc (BMRN) is 57.67.
What is the symbol of BioMarin Pharmaceutical Inc?
The ticker symbol of BioMarin Pharmaceutical Inc is BMRN.
What is the 52-week high of BioMarin Pharmaceutical Inc?
The 52-week high of BioMarin Pharmaceutical Inc is 66.28.
What is the 52-week low of BioMarin Pharmaceutical Inc?
The 52-week low of BioMarin Pharmaceutical Inc is 49.26.
What is the market capitalization of BioMarin Pharmaceutical Inc?
The market capitalization of BioMarin Pharmaceutical Inc is 11.15B.
Is BioMarin Pharmaceutical Inc (BMRN) currently rated as Buy, Hold, or Sell?
According to analysts, BioMarin Pharmaceutical Inc (BMRN) has an overall rating of Buy, with a price target of 89.14.
What is the Earnings Per Share (EPS TTM) of BioMarin Pharmaceutical Inc (BMRN)?
The Earnings Per Share (EPS TTM) of BioMarin Pharmaceutical Inc (BMRN) is 1.82.
